the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jul 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called central serous chorioretinopathy (CSC), which affects the eye and often comes with gastrointestinal issues. Researchers want to see if there is a link between the bacteria in our gut (the gut microbiota) and CSC. They have noticed that patients with CSC frequently have problems with their stomachs, so they will compare the gut bacteria of CSC patients to healthy individuals. Additionally, the trial will involve giving some participants a supplement containing beneficial bacteria called Bifidobacterium for at least a month, while others will receive a placebo (a non-active treatment). The goal is to find out if those taking the supplements recover faster and have fewer relapses compared to those taking the placebo.

To join this trial, participants should be between 18 and 60 years old, diagnosed with acute CSC for six months or less, and have a certain level of vision. They should not have other serious health conditions or specific eye diseases that could affect the results. If eligible, participants can expect to provide a stool sample and take either the Bifidobacterium supplement or a placebo while attending follow-up appointments to monitor their progress. This study could help us understand more about the connection between gut health and eye conditions, which might lead to new treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 60 years
• • Diagnosis of acute central serous chorioretinopathy (CSC) (affected eye: ① FFA and ICGA showing typical CSC manifestations, ② presence of subretinal fluid (SRF) at the macular fovea, ③ disease duration ≤ 6 months)
• • Best Corrected Visual Acuity (BCVA): 53 to 86 letters
• • Other: No significant systemic diseases, signed informed consent, and able to commit to follow-up
• Exclusion Criteria:
• • Presence of significant systemic diseases
• • BCVA of 20/200 or worse
• • Presence of choroidal or retinal atrophy in the macular fovea of the affected eye
• • Presence of choroidal neovascularization (CNV), age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), diabetic retinopathy (DR), choroidal hemangioma, pigment epithelial detachment (PED), etc., in the affected eye
• • High myopia in the affected eye